Long Acting Injectables Tag

Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens

[vc_row css_animation="" row_type="row" use_row_as_full_screen_section="no" type="full_width" angled_section="no" text_align="left" background_image_as_pattern="without_pattern"][vc_column][vc_column_text] This is a Phase 3, open-label, multicenter, randomized, active-controlled noninferiority study to evaluate the efficacy and safety of switching to twice-yearly Lenicapavir (LEN) + Teropavimab (TAB) + Zinlirvimab (ZAB) versus continuing stable baseline regimen (SBR) in virologically suppressed...